Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis
<b>Objective:</b> The course of relapsing–remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (...
Saved in:
Main Authors: | Işıl Peker, Hacer Eroğlu İçli, Belgin Mutluay, Burcu Yüksel, Zeynep Özdemir, Mesrure Köseoğlu, Aysu Şen, Dilek Ataklı, Aysun Soysal, Musa Öztürk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/40 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms
by: Raanan Greenman, et al.
Published: (2025-01-01) -
Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01) -
Clinical and Imaging Features of Familial and Sporadic Multiple Sclerosis
by: Kamal AmirAshjei Asalemi, et al.
Published: (2025-01-01) -
The Inflammatory Chemokine CCL5 and Cancer Progression
by: Donatella Aldinucci, et al.
Published: (2014-01-01) -
Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
by: Carlo Lazzaro, et al.
Published: (2025-01-01)